ICANS stands for immune effector cell-associated neurotoxicity syndrome. It can include confusion, trouble speaking, tremor, sleepiness, seizures, or other neurologic changes after CAR-T therapy.

CAR-T Side Effects: CRS, ICANS, Infection

CAR-T Side Effects and Recovery

Risk guide based on approved care and specialist monitoring. Recent FDA labeling for approved CAR-T products continues to highlight cytokine release syndrome, neurologic toxicity including ICANS, infections, prolonged cytopenias, and hypogammaglobulinemia as major safety issues that require structured monitoring

CAR-T can be very effective for selected blood cancers, but it can also cause serious side effects that need close follow-up. The most important early risks are cytokine release syndrome (CRS) and ICANS, a neurologic toxicity syndrome. Other major concerns include infection, low blood counts, and longer-term immune issues such as hypogammaglobulinemia.

The exact side effects, timing, and intensity can vary by product, cancer type, disease burden, and the patient’s overall health. Some people need inpatient monitoring or closer follow-up because of higher-risk disease or medical complexit

Cytokine Release Syndrome

Cytokine release syndrome, or CRS, is an inflammatory reaction caused by strong immune activation after CAR-T infusion. It can cause fever, chills, low blood pressure, breathing problems, fast heart rate, low oxygen levels, and sometimes organ stress if it becomes severe. FDA labels for approved CAR-T products continue to treat CRS as one of the main boxed or major warnings.

CRS often happens early, which is why many labels require daily monitoring for at least the first 7 days after infusion and continued vigilance afterward. For example, the CARVYKTI label says to monitor patients at least daily for 7 days for signs and symptoms of CRS and to monitor for CRS for at least 2 weeks after infusion.

CRS is usually treated with supportive care and, when needed, tocilizumab and sometimes corticosteroids. Approved-product labels require centers to be ready to recognize and manage it quickly.

Neurologic Side Effects and ICANS

ICANS stands for immune effector cell-associated neurotoxicity syndrome. It can cause confusion, slowed thinking, trouble speaking, handwriting changes, tremor, sleepiness, attention problems, and in more serious cases seizures or severe encephalopathy. FDA labels for CAR-T products warn that neurologic toxicity may occur with or without CRS.

Like CRS, ICANS usually needs early recognition and rapid evaluation. The CARVYKTI label instructs centers to monitor at least daily for 7 days for signs and symptoms of ICANS and to continue watching for at least 2 weeks after infusion.

NCI’s ALL treatment guidance also notes that neurotoxicity has included aphasia, altered mental status, and seizures in CAR-T recipients.

Infection and Low Blood Counts

Infection is one of the most important CAR-T risks. FDA labels for Yescarta, Breyanzi, and other products warn about serious infections and instruct clinicians to monitor patients closely and treat infections appropriately.

Low blood counts, also called cytopenias, can last for weeks after treatment. The Yescarta label says grade 3 or higher cytopenias may continue for several weeks, and the Breyanzi label reports persistent day-29 cytopenias in a substantial proportion of patients.

Patients may need transfusions, growth factor support, infection prevention strategies, and repeated blood count checks during recovery. That is a standard clinical inference from the FDA warnings about prolonged cytopenias and infection risk.

Longer-Term Issues

Some CAR-T side effects can continue or show up after the initial hospital or monitoring period. FDA labels warn about hypogammaglobulinemia, which means low antibody levels that can raise infection risk, and recommend monitoring with replacement therapy when needed.

FDA labels also now include warnings about secondary malignancies, including T-cell malignancies, after treatment with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies.

Some products have additional product-specific long-term concerns. For example, CARVYKTI labeling includes warnings about Parkinsonism and other delayed neurologic toxicities in addition to ICANS.

Part 1

Warning Signs That Need Urgent Medical Help

Patients and caregivers should seek urgent medical help for any of the following warning signs after CAR-T treatment:

Fever after infusion

Trouble breathing

Dizziness or fainting

New confusion or unusual sleepiness

Trouble speaking or writing

Seizure-like activity

Severe weakness

Signs of infection or bleeding

Part 2

Why These Warning Signs Matter

These warning signs reflect the major labeled risks of cytokine release syndrome (CRS), neurologic toxicity, infection, and cytopenias.

A simple patient-facing message is: do not wait to see if these symptoms pass on their own.

Part 1

What Caregivers Should Watch For

After discharge, caregivers should watch closely for early warning signs and help the patient follow the recovery plan. Neurologic symptoms can sometimes be subtle at first, so caregiver observation can be very important.

Fever

Chills

Breathing changes

Confusion

Trouble speaking

Unusual behavior

Severe fatigue

Dizziness

Bleeding

Signs of infection

Part 2

Recovery Checklist

Keep all scheduled follow-up visits

Report fever or neurologic changes immediately

Follow blood test and infection-monitoring plans

Ask when driving and travel restrictions end

Keep medication and emergency contact instructions easy to reach

Make sure a caregiver knows what symptoms need urgent action

Helpful patient-facing note: some current CAR-T product labels still advise patients to remain near a healthcare facility for at least 2 weeks after infusion and to avoid driving for at least 2 weeks. Always follow the specific instructions given by the treatment team.

Who May Need Inpatient or Closer Monitoring

Some patients may need inpatient monitoring or especially close follow-up because of higher disease burden, prior complications, infection risk, product-specific monitoring rules, or concern for severe CRS or neurologic toxicity. FDA labeling for Kymriah notes that high pre-infusion tumor burden is a risk factor for severe CRS in pediatric and young adult B-ALL, which supports closer monitoring in higher-risk situations.

Questions to Ask Your Care Team

Am I eligible for Casgevy, Zynteglo, or both?
Does my level of transfusion dependence make gene therapy reasonable to discuss now?
Is my organ function strong enough for conditioning?
What fertility issues should I discuss before treatment?
How long might the treatment and recovery pathway take?
What are the biggest short-term and long-term risks in my case?
Would transplant still be a better option for me?
What are the alternatives if gene therapy is not the best fit?

FAQ

What is cytokine release syndrome?

CRS is an inflammatory immune reaction after CAR-T infusion. It can cause fever, low blood pressure, breathing problems, and other systemic symptoms, and it may become severe if not treated quickly.

What is ICANS?

ICANS is a neurologic toxicity syndrome linked to immune effector cell therapy. It can cause confusion, trouble speaking, reduced alertness, tremor, and sometimes seizures or severe encephalopathy.

How long do side effects usually last?

The timing varies by product and patient. CRS and ICANS often happen early, especially in the first days after infusion, while infections, low blood counts, and hypogammaglobulinemia may last much longer and require ongoing follow-up.

Can problems happen after discharge?

Yes. FDA labels specifically warn that patients should still be monitored for CRS and neurologic toxicity after the first few days, and some risks such as infection, prolonged cytopenias, and hypogammaglobulinemia can continue after discharge.

How are infections prevented?

Prevention depends on the center and the patient, but usually includes close monitoring, blood count follow-up, and infection-management plans based on the product label and the patient’s immune recovery. FDA labels emphasize monitoring and appropriate treatment of serious infections.

What should caregivers watch for at home?

Caregivers should watch for fever, breathing problems, confusion, trouble speaking, unusual sleepiness, weakness, bleeding, and other signs of infection or neurologic change. These are some of the most important home warning signs after CAR-T.

Clinical Trials:

Medical Disclaimer & Source References
© BEIJING BIOTECH.
Clinical Sources: NCCN, ASCO, ACS, ESMO, CSCO, CACA, ChiCTR.
Treatment Note: Risks such as CRS, neurologic effects, infection, and prolonged low blood counts require specialist monitoring.

Home
Our Treatments
Our Hospitals
Journey Steps
Contact Us
Cancer Second Opinion
Trial Matching
Cancer Treatments HUB
Clinical Trials: How They Work
Treatments HUB
Cancer Types HUB
Caregiver Hub